After spending 20 years at Novartis, Radiopharm Theranostics Ltd. CEO Riccardo Canevari told BioWorld that when he joined Radiopharm he wanted to focus on something different within radiopharmaceuticals where no one was playing. “I believe these new modalities are at the beginning of their potential, much like in the immuno-oncology space years ago. That’s a nice place to be,” he said, but it’s not only about competition, it’s also about understanding what other companies are doing and if there is a disease area or a mechanism of action that is not being explored, he said.
Starpax Biopharma Inc. files for further protection of its anticancer technology that uses magnetically steered bacteria to spread chemotherapy drugs throughout the volume of tumors. Its latest filing describes a method for preparing a subject for a medical intervention with magnetotactic bacteria tethered to treatment, imaging or diagnostic agents.
Insilico Medicine Inc. has patented new cyclin-dependent kinase 12 (CDK12)/cyclin K and/or CDK13 inhibitors reported to be useful for the treatment of cancer, particularly triple-negative breast cancer.
Ajax Therapeutics Inc. has synthesized heterocyclic amide and urea compounds acting as tyrosine-protein kinase JAK2 inhibitors and thus reported to be useful for the treatment of cancer and myelofibrosis.
A Beijing Danatlas Pharmaceutical Technology Co. Ltd. patent describes tricyclic heterocyclic derivatives acting as membrane-associated tyrosine- and threonine-specific Cdc2-inhibitory kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.
Autophagy of cancer cells has been frequently observed during radiotherapy. In addition, pancreatic cancer-associated fibroblasts can compromise the radiotherapeutic effect by promoting the autophagy of the irradiated pancreatic cancer cells.
Seven years since the first approval of two chimeric antigen receptor T-cell therapies for hematological cancers, U.S. and Singapore-based Immunoscape Pte Ltd. is looking to develop novel T-cell receptor (TCR) therapeutics for solid tumors.
The phase II Initium study of Ultimovacs ASA’s therapeutic cancer vaccine in treating unresectable or metastatic malignant melanoma did not meet the primary endpoint. The company framed the loss by saying the UV-1 vaccine still has other indications where it could succeed.
Lawrence Livermore National Laboratory, Leidos Biomedical Research Inc. and Theras Inc. have jointly disclosed new GTPase KRAS (G12D mutant) inhibitors potentially useful for the treatment of cancer.